Patents by Inventor Jong Won Oh

Jong Won Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it
    Patent number: 8470335
    Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: June 25, 2013
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation
    Inventors: Jong Won Oh, Dae Gyun Ahn
  • Recombinant Sars-Cov nsp12 and the Use of Thereof and the Method for Producing it
    Publication number: 20110097730
    Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
    Type: Application
    Filed: June 13, 2008
    Publication date: April 28, 2011
    Applicants: Industry-Academic Cooperation Foundation, Yonsei University, Kookmin University Industry Academy Cooperation Foundation
    Inventors: Jong Won Oh, Dae Gyun Ahn